T cells and colonic subepithelial myofibroblasts: what are they doing in mucosal inflammation

J Gastroenterol. 2007 Jan;42 Suppl 17:29-33.

Interaction between interleukin-17-producing CD4(+) T cells and colonic subepithelial myofibroblasts: what are they doing in mucosal inflammation?

Andoh A, Ogawa A, Bamba S, Fujiyama Y. Department of Internal Medicine, Shiga University of Medical Science, Seta-Tukinowa, Otsu, 520-2192, Japan.

Recent studies have shown alterations and activations in the mucosal immune system in patients with irritable bowel syndrome (IBS) as well as in those with inflammatory bowel disease (IBD). As one of effectors of mucosal inflammation, a new lineage of effector CD4(+) T cells characterized by production of interleukin (IL)-17, the T-helper (Th)-17 lineage, was recently described. Th-17 cells are developmentally and functionally distinct from Th1 and Th2 cells. Here, we discuss the recent concept of low-grade inflammation as a factor associated with the pathophysiology of IBS. Furthermore, based on the data from our laboratory, interaction between Th-17 cells and colonic subepithelial myofibroblasts may play an important role in the pathophysiology of IBS and IBD.

PMID: 17238023 [PubMed - in process]

Full Article Available Online

{mosgoogle}

{mos_sb_discuss:11}

Set as favorite

Bookmark

Email this

Comments (0) Add Comment